Viscosupplementation Market Overview
The global viscosupplementation market has
witnessed significant growth in recent years, driven by the rising prevalence
of osteoarthritis and the increasing aging population. Viscosupplementation is
a minimally invasive therapy that involves the injection of a gel-like
substance, typically hyaluronic acid, into the joint space to provide
lubrication and cushioning. This procedure aims to alleviate pain and improve
joint mobility in individuals suffering from osteoarthritis, a degenerative
joint disease.
The viscosupplementation
market is projected to grow from USD 2.602
Billion in 2024 to USD 5.513 billion by 2032, exhibiting a compound annual
growth rate (CAGR) of 9.84% during the forecast period (2024 - 2032).
The viscosupplementation market is witnessing a
surge in demand due to the growing awareness among both healthcare
professionals and patients about the benefits of this therapy. Advancements in
technology have also led to the development of innovative viscosupplementation
products, contributing to market expansion.
Viscosupplementation
injections, also known as
hyaluronic acid injections, have gained popularity as a non-surgical
alternative for managing osteoarthritis-related pain. The therapy works by
restoring the viscosity and elasticity of synovial fluid, the natural lubricant
in joints, which tends to diminish in osteoarthritis patients. This enhances
joint lubrication, reduces friction, and alleviates pain, offering relief to
those with mild to moderate osteoarthritis symptoms.
Viscosupplementation therapy is commonly
administered in the knee joint, although it can be used in other joints such as
the hip and shoulder. The outpatient nature of this therapy makes it convenient
for patients, as it eliminates the need for hospitalization. The procedure is
generally well-tolerated with minimal side effects, making it a preferred
choice for individuals seeking a less invasive treatment option for
osteoarthritis.
The global viscosupplementation market is
poised for continued growth, driven by the increasing prevalence of
osteoarthritis and the growing acceptance of viscosupplementation therapy as an
effective and safe treatment option. As research and development efforts
continue to enhance the efficacy of viscosupplementation injections, the market
is expected to witness further advancements, providing hope for individuals
seeking relief from osteoarthritis-related joint pain.
Major Key Players:
MRFR in its expert analysis of the global viscosupplementation
companies included are Hoffmann-La
Roche, Sanofi, Allergan, Anika Therapeutics Inc., Bioventus, Regen Lab SA,
Zimmer Biomet, Smith & Nephew Plc, Ferring B.V., Fidia Farmaceutici S.P.A.,
and others.
Recent improvements in product pipeline R&D
offer significant prospects for the growth of the viscosupplementation market.
In hospitals, viscosupplementation is offered as an outpatient operation, and
the patient is released a few hours later. A general physician or an
orthopedist from the same institution would frequently propose
viscosupplementation operations that are carried out in a hospital. Patients
typically prefer hospitals in developing nations where there are few orthopedic
clinics. Patients must visit the hospital on a certain day in these nations,
where orthopedic doctors frequently visit professors. Furthermore, because
viscosupplementation procedures don't require additional expenditure, the
majority of multispecialty hospitals around the world provide them.
Segment Analysis
The global viscosupplementation market includes
segments like hyaluronic acid type, procedure type, application, and end-user
to facilitate an easy understanding of the market. This method provides a
closer look at the market that can ensure better growth in the coming years.
By hyaluronic acid type, the global market
report for the viscosupplementation market includes stabilized hyaluronic acid
and standard hyaluronic acid. The stabilized hyaluronic acid segment has the
largest market share as its impurity level is close to zero.
By procedure type, the market report on the
viscosupplementation market comprises three-injection procedure,
single-injection procedure, and five-injection procedure. The three-injection
procedure segment has a better opportunity to maintain its robust growth as it
is lower in price when compared with the single-injection procedures and takes
less time than the five-injection procedure. Its CAGR could cross a
valuation of USD 2602.58 million during the forecast period.
By application, the market report covering the
viscosupplementation market includes knee arthritis and hip osteoarthritis. The
knee arthritis segment has a better market share than hip osteoarthritis.
By end user, the market report can be segmented
into hospitals & clinics and ambulatory surgical centers. The hospitals
& clinics segment has a larger share owing to people preferring this setup
for their treatment.
Regional Analysis
The Americas stood at the top in 2017 and has
the opportunity to score the highest CAGR in the coming years. The demand for
knee replacement surgeries with increasing thrust from the minimally-invasive
procedures can trigger the growth of viscosupplementation procedures.
The Asia-Pacific region has the second-largest
market share and can score well-past USD 447.24 million valuations by 2023
with a CAGR of 10.48% during the forecast period. The region would witness
contributions made by countries like China, India, and others. These are
countries with high expenditure capacity and huge patient pool. In Europe, the
growth would be the most in the UK, where increased awareness regarding the
procedure would trigger better growth.
T-Cell Lymphoma Therapeutics Industry Market
Aspergillosis
Treatment Market
